Xeloda (capecitabine) - Risk of severe skin reactions

Hoffmann-La Roche Limited (Roche), in consultation with Health Canada, would like to inform you of the risk of severe cutaneous reactions associated with the use of Xeloda. XELODA is authorized for the following indications: 1. Colorectal cancer: Adjuvant treatment of patients with stage III (Dukes’ stage C) colon cancer; first-line treatment of patients with metastatic colorectal cancer; treatment of metastatic colorectal cancer, in combination with oxaliplatin, following failure of irinotecan-containing combination chemotherapy; 2. Breast cancer: Treatment of patients with advanced or metastatic breast cancer, in combination with docetaxel, after failure of prior anthracycline containing chemotherapy; treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane, unless therapy with a taxane is clinically contraindicated. Read more here.